Searchable abstracts of presentations at key conferences in endocrinology

ea0041ep673 | Female Reproduction | ECE2016

Improvement of beta-cell function with DPP-4 inhibitor alogliptin vs alogliptin in combination with pioglitazone as a potential treatment target in metformin treated PCOS with persistent high metabolic risk: randomized pilot study

Jensterle Mojca , Goricar Katja , Janez Andrej

Introduction: High conversion rates to impaired glucose tolerance (IGT) and diabetes in PCOS indicate that current treatment strategy with lifestyle modification and metformin is insufficient. Preservation of β-cell function remains unaddressed although it is declined by 80% long before IGT is identified. Alogliptin is selective dipeptidyl peptidase-4 inhibitor improving insulin sensitivity (IS) and β-cell function. Pioglitazone predominantly improv...

ea0081p163 | Pituitary and Neuroendocrinology | ECE2022

Clinical applicability of using SAGIT instrument and AcroQol in the management of patients with acromegaly

Herman Rok , Goricar Katja , Janez Andrej , Jensterle Mojca

Objective: We aimed to evaluate the ability of SAGIT Instrument and AcroQoL questionnaire to discriminate acromegaly control status and to correlate SAGIT scores to AcroQoL results in a cohort of the national referral centre.Methods: Cross-sectional study included 72 patients followed between 2000 and 2020. We retrospectively determined SAGIT score at the diagnosis. Based on the data from the most recent follow up and additional telephone interviews, we ...

ea0090rc10.3 | Rapid Communications 10: Diabetes, Obesity, Metabolism and Nutrition 2 | ECE2023

The maintenance of long-term weight loss after semaglutide withdrawal in obese women with PCOS treated with metformin: A 2-year observational study

Jensterle Mojca , Ferjan Simona , Goricar Katja , Janez Andrej

Background: Withdrawal of anti-obesity medication is frequently followed by weight regain due to compensatory biological changes that prevent the maintenance of long-term weight loss. In STEP 1 trial extension participants regained two-thirds of their prior weight loss during the 1-year off-treatment follow-up period after withdrawal of semaglutide 2.4 mg and discontinuation of active lifestyle intervention support. There are some studies implying that metformin might attenuat...

ea0063gp247 | Disturbances of Reproduction | ECE2019

The efficacy of long-term metformin treatment in overweight and obese women with PCOS: A 10-year database study

Jensterle Mojca , Aleksandra Kravos Nika , Goricar Katja , Janez Andrej

Context: Metformin is an established therapy for women with PCOS and pre-diabetes or diabetes when lifestyle modification is insufficient. Metformin should also be considered in women with PCOS with BMI≥25 kg/m2 independently of the presence of metabolic disturbances. However, its long-term efficacy in this subset of patients is inadequately studied.Aim: We analyzed collection data of 10 years for the efficacy of metformin on body mass (...

ea0037ep590 | Obesity and cardiovascular endocrinology | ECE2015

Genetic variation in GLP1 receptor is associated with interindividual differences in weight lowering potential of liraglutide in obese women with PCOS

Jensterle Mojca , Pirs Bostjan , Goricar Katja , Dolzan Vita , Janez Andrej

Objective: The weight lowering potential of glucagon-like peptide (GLP) 1 receptor agonists (RAs) is interindividually different and clinically unpredictable. The potential role of genetic variability of GLP1R on body weight response to GLP1 RA has not yet been evaluated. The aim of the study was to assess the effect of common non-synonymous GLP1R single nucleotide polymorphisms (SNPs) rs6923761 and rs10305420 on weight loss in response to long acting GLP1 RA liraglut...

ea0070aep49 | Adrenal and Cardiovascular Endocrinology | ECE2020

Comparison of incidence and characteristics of non-functioning and autonomous cortisol secreting adrenal incidentaloma across different BMI and age distribution

Podbregar Ana , Janez Andrej , Goricar Katja , Jensterle Mojca

Background: The relationship between obesity, metabolic traits and adrenal incidentaloma (AI) in clinical studies have been discussed mainly in one direction: as the consequences of mild autonomous cortisol secretion in autonomous cortisol secreting AI (ACS) and as possible consequences of minimal hormonal secretion not detectable by current diagnostic methods in non-functioning (NF) AI. However, the observed anabolic and mitogenic effects of insulin on adrenal cortex from pre...

ea0070aep504 | Diabetes, Obesity, Metabolism and Nutrition | ECE2020

Genetic variability in antioxodative and inflammatory pathways modifies the risk for PCOS and influences metabolic profile of the syndrome

Herman Rok , Jensterle Mojca , Janez Andrej , Goricar Katja , Dolzan Vita

Background: Polycystic ovary syndrome (PCOS) is a complex endocrine and metabolic disorder of multifactorial etiopathology likely to involve the interactions between genetics and lifestyle. Chronic inflammation and oxidative stress (OS) may participate in the pathophysiology of the syndrome. The question of the extent to which OS and inflammation are causally related to the development of the syndrome and metabolic complications remains unanswered. Furthermore, the role of NLR...

ea0081p28 | Adrenal and Cardiovascular Endocrinology | ECE2022

Comparison of plasma metanephrines in patients with cyanotic and acyanotic congenital heart disease

Jensterle Mojca , Podbregar Ana , Janez Andrej , Rakusa Matej , Goricar Katja , Prokselj Katja

Background: Pheochromocytomas (PHEO) and paragangliomas (PGL) are rare neuroendocrine tumors that can lead to life-threatening conditions. The diagnosis of PHEO/PGL is established by measuring normetanephrine and metanephrine. Biochemical detection usually precedes clinical diagnosis of PHEO/PGL by several years. Co-occurrence of cyanotic congenital heart disease (CCHD) and PHEO/PGL has been reported but potential association remains unclear. We aimed to compare plasma metanep...

ea0090p365 | Diabetes, Obesity, Metabolism and Nutrition | ECE2023

Metabolic abnormalities in adult population with spinal muscular atrophy

Rakusa Matej , Firbas Dejan , Rudolf Tjasa , Goricar Katja , Janez Andrej , Jensterle Mojca

Background: Spinal muscular atrophy (SMA) is hereditary, degenerative, neuro-muscular disease of lower motor neurone that leads to muscle weakness and atrophy. Several metabolic disturbances such as impaired glucose tolerance (IGT), insulin resistance (IR), hypoglycaemia and dyslipidaemia can be present. Most studies were done in children, with more severe forms of SMA. We aimed to assess body composition, IR, glucose and lipid metabolism in adult patients with SMA type 2 and ...